# Lou Lange

> Lou Lange is a company founder, executive, and general partner at Asset Management Ventures. He led CV Therapeutics through its 1996 IPO and 2009 acquisition by Gilead, subsequently founded other companies, and is a Bitterroot Bio cofounder. His institutional service includes Scripps Research and the University of Rochester, where he established a chemistry professorship in memory of his parents.

- **Role:** General Partner at Asset Management Ventures; Cofounder of Bitterroot Bio
- **Organizations:** Asset Management Ventures, Bitterroot Bio, CV Therapeutics, Gilead Sciences, Rapidscan Pharma Solutions, Cardiogen Sciences, Amygdala Neurosciences, Audentes Therapeutics, NewAmsterdam Pharma, Scripps Research, University of Rochester, Harvard University, Washington University, Longwood Fund
- **Education:** BA in Chemistry, University of Rochester, MD, Harvard University, PhD in Biological Chemistry, Harvard University
- **Known for:** Led CV Therapeutics through its 1996 IPO and 2009 acquisition by Gilead., Founded Cardiogen Sciences, acquired by Audentes in 2015., Established the Louis and Dorothy Lange Professorship in Chemistry at the University of Rochester in memory of his parents.

## Career timeline

- **1970** — Graduated from the University of Rochester with a BA in chemistry.
- **1980** — Joined the faculty of Washington University.
- **1990** — Became a full professor at Washington University.
- **1992** — Began serving as chairman and CEO of CV Therapeutics in August.
- **1996** — Led CV Therapeutics through its IPO.
- **2009** — CV Therapeutics acquired by Gilead on April 17, following an announced approximately $1.4 billion agreement; Lange subsequently advised Gilead.
- **2010** — Cofounded Rapidscan Pharma Solutions; received Rochester’s Distinguished Alumnus Award.
- **2014** — Founded Cardiogen Sciences.
- **2015** — Cardiogen acquired by Audentes; Lange joined its board. Amygdala Neurosciences founded, with Lange as executive chairman and founder.
- **2021** — Joined the NewAmsterdam Pharma predecessor board.
- **2022** — Began current-company board service at NewAmsterdam Pharma in November.
- **2024** — Scripps Research announced his appointment to its board on November 19.

## Achievements

- Led CV Therapeutics through its 1996 IPO and 2009 acquisition by Gilead.
- Founded Cardiogen Sciences, acquired by Audentes in 2015.
- Established the Louis and Dorothy Lange Professorship in Chemistry at the University of Rochester in memory of his parents.
- Received the University of Rochester’s 2010 Distinguished Alumnus Award, School of Arts and Sciences.

## Latest updates

- **2024-11** — Scripps Research announced Lange’s appointment to its board alongside Benjamin Cravatt.

## Links

- Website: https://brbio.com/team/lou-lange-md-phd/

---

Profile page: https://yespress.io/lou-lange
Published by YesPress — https://yespress.io
Last updated: 2026-10-11